Conditions

This post was originally published on this site A medicine being developed to treat stroke patients may help protect the brain from Alzheimer’s disease by suppressing the accumulation of toxic amyloid-beta during the early stages of the disease and preventing memory loss, a mouse study shows. The study “3K3A-activated protein C blocks amyloidogenic BACE1 pathway…

This post was originally published on this site United Neuroscience’s Alzheimer’s vaccine candidate UB-311 was found safe and well-tolerated, triggering an antibody response against beta-amyloid in most of the patients, according to Phase 2a trial results. “These early results suggest a clinical response and support the continued and rapid development of UB-311. The intent of this Phase 2a study was…

This post was originally published on this site Alzheimer’s disease patients who take anti-epileptic therapies have a higher number of accumulated days spent in the hospital than those not prescribed this type of medication, a study reports. The study, “Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer’s Disease,” was published in The…

This post was originally published on this site Using a new type of approach called epigenetics, researchers were able to temporarily rescue memory and cognitive function in a mouse model of Alzheimer’s disease. The study showed that epigenetic changes — external modifications to DNA to turn genes on or off without changing the actual DNA…

This post was originally published on this site Two Phase 3 trials — CREAD 1 and CREAD 2 — evaluating crenezumab as a therapy for early Alzheimer’s disease have been discontinued, Genentech announced. The decision was based on an interim analysis by an independent data monitoring committee that ruled that crenezumab was unlikely to meet its…